Predicting Acute Kidney Injury with Nephrotoxic Burden in Noncritical Patients

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Key Points: The developed dynamic model for predicting progression to stage 2 or higher AKI using multicenter data had robust performance. Clinical decision support implementation of the developed model could help prevent AKI progression. Kinetic eGFR, nephrotoxic drug burden, and BUN were the top features and remained the same across the models and sites. Background: AKI is an abrupt decline in kidney function that occurs in about 20% of hospitalized admissions and may lead to irreversible kidney damage. Methods: We developed and externally validated deep learning models to dynamically predict progression to stage 2 or higher AKI defined by Kidney Disease Improving Global Outcomes serum creatinine criteria within the next 48 hours. We used an extensive set of predictors including demographics, admission source, comorbidities, medications, laboratory, and vitals measurements. Results: Our retrospective study includes adult noncritical care patients at the University of Pittsburgh Medical Center (UPMC; 2018–2022; n =39,755) and the University of Florida Health (UFH; 2012–2019; n =122,324). In the UFH and UPMC development cohort, the mean age was 55 and 71 and 55% ( n =47,350) and 54% ( n =15,128) were female, respectively. Stage 2 or higher AKI occurred in 3% ( n =3257) and 8% ( n =2296) of UFH and UPMC patients, respectively. Area under the receiver operating characteristic curve values with 95% confidence interval (CI) ranged between 0.77 (95% CI, 0.75 to 0.78; UPMC Model—model trained on UPMC patients) and 0.81 (95% CI, 0.79 to 0.82; UFH Model—model trained on University of Florida patients) for the UFH test cohort and between 0.79 (95% CI, 0.78 to 0.8; UFH Model) and 0.83 (95% CI, 0.82 to 0.84; UPMC Model) for the UPMC test cohort. UFH-UPMC Model achieved an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.80 to 0.83) for UFH and 0.82 (95% CI, 0.81 to 0.84) for UPMC test cohorts. Kinetic eGFR, nephrotoxic drug burden, and BUN remained the features with the highest influence across the models and institutions. Conclusions: The model developed using multicenter data had robust performance, suggesting that implementation could help prevent AKI progression.
Funding Information
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK120784)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK120784)
  • National Center for Advancing Translational Sciences (UL1 TR000064)
  • National Center for Advancing Translational Sciences (UL1 TR001427)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121730)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK120784)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK120784)
  • National Center for Advancing Translational Sciences (UL1 TR000064)
  • National Center for Advancing Translational Sciences (UL1 TR001427)

This publication has 39 references indexed in Scilit: